A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer

Clin Cancer Res. 2020 Jan 1;26(1):9-10. doi: 10.1158/1078-0432.CCR-19-3072. Epub 2019 Oct 31.

Abstract

Reliable approaches to predict residual disease prior to primary debulking surgery have been sought to further personalize surgical approaches. Reliance on molecular biomarkers alone in a complex clinical environment is challenging and algorithms that incorporate both molecular and clinical features may need to be considered.See related article by Heitz et al., p. 213.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Biomarkers
  • Carcinoma, Ovarian Epithelial*
  • Cytoreduction Surgical Procedures
  • Female
  • Humans
  • Neoplasm, Residual
  • Ovarian Neoplasms*

Substances

  • Biomarkers